Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 21, 2024Open Access

Truncated Complement Factor H Y402 Gene Therapy Cures C3 Glomerulonephritis

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLindsey A. ChewDGDaniel GrigsbyCHC. Garren Hester

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Chew et al. (2024) studied this question.

synapsesocial.com/papers/68e57c19b6db64358751b2f8https://doi.org/10.1101/2024.09.17.613471
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Gliosis-dependent expression of complement factor H truncated variants attenuates retinal neurodegeneration following ischemic injury2024 · 10 citations
  2. 2Therapeutic Evaluation of a C3-Targeting Small Nucleic Acid Drug in a Spontaneous Humanized C3 Glomerulopathy Mouse Model 22568452026
  3. 3Gain-of-function factor H–related 5 protein impairs glomerular complement regulation resulting in kidney damage2021 · 23 citations
  4. 4Safety and Efficacy of cceAAV-aflibercept-Fc-YTE (F-CRG-B191): A Gene Therapy for Neovascular Age-Related Macular Degeneration2026
  5. 5Preclinical development of a dual targeting bicistronic gene therapy approach for the treatment of wet age-related macular degeneration2024